Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2002

View Archived Issues

Atugen and Kinetek sign technology evaluation agreement in oncology

Scancell develops apoptosis-inducing and anti-growth factor antibodies

ZD-0473 associated with manageable toxicity, activity in hormone-refractory prostate cancer

WX-G250 shows antitumor activity and very good tolerance in RCC

Phase II results for atrasentan in prostate cancer patients reported in Birmingham

U.K. investigators evaluate intravesical MeGLA in superficial bladder cancer patients

S-1360, representative of a new class of anti-HIV agents

HuMax-CD4 granted fast track designation in rheumatoid arthritis

INGN-201 registered as Advexin

Avant signs research agreement with International Vaccine Institute for cholera vaccine

Lexicon identifies protein target for atherosclerosis drug development

Phase IIb trial of methylnaltrexone begins for narcotic-induced constipation

DPC-083 effective and well tolerated in both antiretroviral-naive and NNRTI-resistant patients

Femara shows significant survival advantage over tamoxifen in advanced postmenopausal breast cancer

BTG acquires rights to new class of piperazine derivatives for the treatment of HIV

Results of extension study of infliximab in psoriasis patients

Titan receives milestone payment for Spheramine program

Triterpenoid possessing antiproliferative, proapoptotic and differentiation-inducing effects

Korea research center prepares carbapenem antibacterial compounds

Xanthine inhibitors of dipeptidyl-peptidase IV in development at Novo Nordisk

RiboTargets identifies compounds for use in viral infections

Pyrimidine derivatives with affinity for 5-HT1A receptors useful for neurodegenerative disorders

Ortho-McNeil claims compounds with potential utility in asthma, etc.

Treatment of refractory urinary dysfunction with resiniferatoxin

Glycosylated curcumin derivatives for use in virus-associated tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...